Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.22
BRKR's Cash-to-Debt is ranked lower than
61% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. BRKR: 1.22 )
Ranked among companies with meaningful Cash-to-Debt only.
BRKR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16  Med: 1.5 Max: N/A
Current: 1.22
Equity-to-Asset 0.38
BRKR's Equity-to-Asset is ranked lower than
74% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BRKR: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
BRKR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.42 Max: 0.68
Current: 0.38
0.15
0.68
Interest Coverage 14.77
BRKR's Interest Coverage is ranked lower than
64% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.15 vs. BRKR: 14.77 )
Ranked among companies with meaningful Interest Coverage only.
BRKR' s Interest Coverage Range Over the Past 10 Years
Min: 7.92  Med: 14.72 Max: N/A
Current: 14.77
Piotroski F-Score: 7
Altman Z-Score: 3.86
Beneish M-Score: -2.40
WACC vs ROIC
12.06%
26.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 11.00
BRKR's Operating Margin % is ranked higher than
72% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. BRKR: 11.00 )
Ranked among companies with meaningful Operating Margin % only.
BRKR' s Operating Margin % Range Over the Past 10 Years
Min: 5.83  Med: 9.6 Max: 13.34
Current: 11
5.83
13.34
Net Margin % 9.53
BRKR's Net Margin % is ranked higher than
83% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.05 vs. BRKR: 9.53 )
Ranked among companies with meaningful Net Margin % only.
BRKR' s Net Margin % Range Over the Past 10 Years
Min: 3.13  Med: 6.06 Max: 9.58
Current: 9.53
3.13
9.58
ROE % 22.08
BRKR's ROE % is ranked higher than
90% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. BRKR: 22.08 )
Ranked among companies with meaningful ROE % only.
BRKR' s ROE % Range Over the Past 10 Years
Min: 7.03  Med: 14.91 Max: 23.93
Current: 22.08
7.03
23.93
ROA % 8.73
BRKR's ROA % is ranked higher than
85% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. BRKR: 8.73 )
Ranked among companies with meaningful ROA % only.
BRKR' s ROA % Range Over the Past 10 Years
Min: 2.94  Med: 5.66 Max: 11.34
Current: 8.73
2.94
11.34
ROC (Joel Greenblatt) % 35.19
BRKR's ROC (Joel Greenblatt) % is ranked higher than
74% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. BRKR: 35.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BRKR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.4  Med: 30.31 Max: 54.93
Current: 35.19
19.4
54.93
3-Year Revenue Growth Rate -3.10
BRKR's 3-Year Revenue Growth Rate is ranked lower than
68% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. BRKR: -3.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BRKR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 43.4
Current: -3.1
0
43.4
3-Year EBITDA Growth Rate 6.50
BRKR's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. BRKR: 6.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BRKR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.75 Max: 145.1
Current: 6.5
0
145.1
3-Year EPS without NRI Growth Rate 25.60
BRKR's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. BRKR: 25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BRKR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.1 Max: 59.6
Current: 25.6
0
59.6
GuruFocus has detected 2 Warning Signs with Bruker Corp $BRKR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BRKR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BRKR Guru Trades in Q1 2016

Joel Greenblatt 712,459 sh (New)
Paul Tudor Jones 38,748 sh (New)
Jim Simons 441,110 sh (New)
George Soros Sold Out
Murray Stahl 18,535 sh (-25.64%)
NWQ Managers 340,590 sh (-46.08%)
Mariko Gordon 102,527 sh (-47.48%)
» More
Q2 2016

BRKR Guru Trades in Q2 2016

Jim Simons 1,152,510 sh (+161.27%)
Mariko Gordon Sold Out
Murray Stahl 17,976 sh (-3.02%)
Paul Tudor Jones 27,700 sh (-28.51%)
NWQ Managers 162,115 sh (-52.40%)
Joel Greenblatt 251,600 sh (-64.69%)
» More
Q3 2016

BRKR Guru Trades in Q3 2016

NWQ Managers 401,745 sh (+147.81%)
Murray Stahl 18,350 sh (+2.08%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Jim Simons 429,410 sh (-62.74%)
» More
Q4 2016

BRKR Guru Trades in Q4 2016

Steven Cohen 48,800 sh (New)
Joel Greenblatt 13,320 sh (New)
Murray Stahl 19,630 sh (+6.98%)
NWQ Managers 394,886 sh (-1.71%)
Jim Simons 28,610 sh (-93.34%)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:CRL, NAS:PRAH, NYSE:ALR, OTCPK:CZMWY, NAS:PRXL, NAS:ICLR, NAS:NEOG, NAS:EXAS, NYSE:BIO.B, NYSE:PKI, OTCPK:BMXMF, NAS:QGEN, NAS:AXDX, NAS:DXCM, NAS:MYGN, NAS:ABAX, OTCPK:ERFSF, NAS:ALOG, NAS:GHDX, NAS:FMI » details
Traded in other countries:BKD.Germany,
Bruker Corp is designer and manufacturer of life science & materials research systems in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics industries.

Bruker Corp was incorporated in Delaware and is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. The Company manufactures and distributes field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also designs, manufactures and markets high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Compa

Ratios

vs
industry
vs
history
PE Ratio 26.18
BRKR's PE Ratio is ranked higher than
64% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. BRKR: 26.18 )
Ranked among companies with meaningful PE Ratio only.
BRKR' s PE Ratio Range Over the Past 10 Years
Min: 7.21  Med: 33.27 Max: 67.25
Current: 26.18
7.21
67.25
Forward PE Ratio 23.47
BRKR's Forward PE Ratio is ranked lower than
56% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. BRKR: 23.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.18
BRKR's PE Ratio without NRI is ranked higher than
64% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. BRKR: 26.18 )
Ranked among companies with meaningful PE Ratio without NRI only.
BRKR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.21  Med: 33.27 Max: 67.25
Current: 26.18
7.21
67.25
Price-to-Owner-Earnings 67.58
BRKR's Price-to-Owner-Earnings is ranked lower than
85% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. BRKR: 67.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BRKR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.85  Med: 44.51 Max: 6933.33
Current: 67.58
10.85
6933.33
PB Ratio 5.76
BRKR's PB Ratio is ranked lower than
67% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. BRKR: 5.76 )
Ranked among companies with meaningful PB Ratio only.
BRKR' s PB Ratio Range Over the Past 10 Years
Min: 1.61  Med: 4.35 Max: 8.92
Current: 5.76
1.61
8.92
PS Ratio 2.50
BRKR's PS Ratio is ranked higher than
64% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. BRKR: 2.50 )
Ranked among companies with meaningful PS Ratio only.
BRKR' s PS Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.82 Max: 2.99
Current: 2.5
0.5
2.99
Price-to-Free-Cash-Flow 42.51
BRKR's Price-to-Free-Cash-Flow is ranked lower than
70% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. BRKR: 42.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BRKR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.93  Med: 26.48 Max: 146.34
Current: 42.51
9.93
146.34
Price-to-Operating-Cash-Flow 30.59
BRKR's Price-to-Operating-Cash-Flow is ranked lower than
75% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. BRKR: 30.59 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BRKR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.71  Med: 20.21 Max: 50.83
Current: 30.59
5.71
50.83
EV-to-EBIT 22.01
BRKR's EV-to-EBIT is ranked higher than
58% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. BRKR: 22.01 )
Ranked among companies with meaningful EV-to-EBIT only.
BRKR' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.2  Med: 19.7 Max: 36.2
Current: 22.01
5.2
36.2
EV-to-EBITDA 16.85
BRKR's EV-to-EBITDA is ranked higher than
55% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. BRKR: 16.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
BRKR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.7  Med: 16.15 Max: 36.2
Current: 16.85
4.7
36.2
PEG Ratio 29.11
BRKR's PEG Ratio is ranked lower than
97% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. BRKR: 29.11 )
Ranked among companies with meaningful PEG Ratio only.
BRKR' s PEG Ratio Range Over the Past 10 Years
Min: 0.09  Med: 1.03 Max: 20.84
Current: 29.11
0.09
20.84
Shiller PE Ratio 42.24
BRKR's Shiller PE Ratio is ranked lower than
55% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. BRKR: 42.24 )
Ranked among companies with meaningful Shiller PE Ratio only.
BRKR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 35.08  Med: 50.2 Max: 101.93
Current: 42.24
35.08
101.93
Current Ratio 2.42
BRKR's Current Ratio is ranked lower than
54% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. BRKR: 2.42 )
Ranked among companies with meaningful Current Ratio only.
BRKR' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.17 Max: 4.16
Current: 2.42
1.26
4.16
Quick Ratio 1.58
BRKR's Quick Ratio is ranked lower than
66% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. BRKR: 1.58 )
Ranked among companies with meaningful Quick Ratio only.
BRKR' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.3 Max: 3.14
Current: 1.58
0.55
3.14
Days Inventory 191.29
BRKR's Days Inventory is ranked lower than
84% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. BRKR: 191.29 )
Ranked among companies with meaningful Days Inventory only.
BRKR' s Days Inventory Range Over the Past 10 Years
Min: 179.35  Med: 216.33 Max: 264.16
Current: 191.29
179.35
264.16
Days Sales Outstanding 55.25
BRKR's Days Sales Outstanding is ranked higher than
62% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. BRKR: 55.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
BRKR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.76  Med: 59.73 Max: 65.48
Current: 55.25
52.76
65.48
Days Payable 36.17
BRKR's Days Payable is ranked lower than
64% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. BRKR: 36.17 )
Ranked among companies with meaningful Days Payable only.
BRKR' s Days Payable Range Over the Past 10 Years
Min: 26.4  Med: 29.9 Max: 147.25
Current: 36.17
26.4
147.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.64
BRKR's Dividend Yield % is ranked lower than
70% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. BRKR: 0.64 )
Ranked among companies with meaningful Dividend Yield % only.
BRKR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.44 Max: 0.76
Current: 0.64
0.14
0.76
Forward Dividend Yield % 0.64
BRKR's Forward Dividend Yield % is ranked lower than
68% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.13 vs. BRKR: 0.64 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.65
BRKR's 5-Year Yield-on-Cost % is ranked lower than
79% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. BRKR: 0.65 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BRKR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14  Med: 0.36 Max: 0.76
Current: 0.65
0.14
0.76
3-Year Average Share Buyback Ratio 1.40
BRKR's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. BRKR: 1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BRKR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.1  Med: -5.85 Max: 0
Current: 1.4
-22.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 26.17
BRKR's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.95 vs. BRKR: 26.17 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BRKR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.69  Med: 14.44 Max: 103.75
Current: 26.17
2.69
103.75
Price-to-Tangible-Book 10.17
BRKR's Price-to-Tangible-Book is ranked lower than
72% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.33 vs. BRKR: 10.17 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BRKR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.47  Med: 5.36 Max: 10.59
Current: 10.17
1.47
10.59
Price-to-Intrinsic-Value-Projected-FCF 2.81
BRKR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. BRKR: 2.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BRKR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.86 Max: 8.24
Current: 2.81
0.91
8.24
Price-to-Median-PS-Value 1.37
BRKR's Price-to-Median-PS-Value is ranked lower than
73% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. BRKR: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BRKR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 0.98 Max: 8.92
Current: 1.37
0.33
8.92
Price-to-Graham-Number 3.44
BRKR's Price-to-Graham-Number is ranked lower than
54% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. BRKR: 3.44 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BRKR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.08  Med: 2.93 Max: 17.32
Current: 3.44
1.08
17.32
Earnings Yield (Greenblatt) % 4.50
BRKR's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. BRKR: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BRKR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 5.1 Max: 19.4
Current: 4.5
2.8
19.4
Forward Rate of Return (Yacktman) % 1.98
BRKR's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. BRKR: 1.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BRKR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.1  Med: 9.4 Max: 110.4
Current: 1.98
-3.1
110.4

More Statistics

Revenue (TTM) (Mil) $1,611
EPS (TTM) $ 0.95
Beta1.39
Short Percentage of Float5.58%
52-Week Range $19.59 - 29.85
Shares Outstanding (Mil)160.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,642 1,715 1,782
EPS ($) 1.05 1.21 1.35
EPS without NRI ($) 1.05 1.21 1.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.08 0.08
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
Largest Insiders' Trades of the Week Jun 10 2016 
Mariko Gordon Nearly Doubles Stake in Forward Air Jan 04 2016 
Mariko Gordon Acquires Five New Stakes in Second Quarter Aug 27 2015 
Insiders New Buys: Bruker Corp Jun 22 2015 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 

More From Other Websites
Bruker Announces Quarterly Dividend Feb 21 2017
Bruker Corp. :BRKR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 Feb 16 2017
Bruker Corp. :BRKR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 Feb 15 2017
Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance Feb 14 2017
Edited Transcript of BRKR earnings conference call or presentation 13-Feb-17 9:45pm GMT Feb 14 2017
Bruker tops Street 4Q forecasts Feb 13 2017
Bruker tops Street 4Q forecasts Feb 13 2017
BRUKER CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 13 2017
Bruker Reports Fourth Quarter and Fiscal Year 2016 Financial Results Feb 13 2017
Q4 2016 Bruker Corp Earnings Release - After Market Close Feb 13 2017
Bruker Introduces MALDI PharmaPulse™ 2.0 Solution at SLAS 2017 for 100x Faster Mass... Feb 06 2017
Bruker Announces Date and Time of Fourth Quarter 2016 Earnings Release and Webcast Jan 30 2017
Bruker Announces Unique and Comprehensive Workflows For Biopharmaceutical Characterization,... Jan 24 2017
Bruker Announces Acquisition of Nanoindenting Leader Hysitron Jan 24 2017
Coverage initiated on Bruker by Deutsche Bank Jan 18 2017
BRUKER CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 09 2017
Bruker Corp. breached its 50 day moving average in a Bullish Manner : BRKR-US : January 9, 2017 Jan 09 2017
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite Jan 05 2017
Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging Jan 05 2017
Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and... Jan 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)